| Modulating the nitric oxide - cyclic GMP pathway in the pressure-overloaded left ventricle and group II pulmonary hypertension. | |
| | |
MedLine Citation:
|
PMID: 20939842 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Group II pulmonary hypertension (PH) commonly occurs in the setting of a pressure-overloaded left ventricle (LV) which is also conducive to the development of heart failure with preserved ejection fraction. Population trends and a high prevalence of underlying causative conditions, such as essential hypertension or aortic stenosis, have increased the awareness of the pressure-overloaded LV and associated group II pulmonary hypertension. Patients often exhibit poor exercise tolerance and signs of heart failure indistinguishable from systolic heart failure; but effective medical treatments in this area have been lacking. Recent preclinical work has shed light on how the down-regulated nitric oxide - cyclic GMP pathway (within the myocardium and pulmonary vasculature) contributes to the pathophysiology of these associated conditions. This article will discuss the impact of the nitric oxide - cyclic GMP pathway on the pathogenesis of the pressure-overloaded LV and group II pulmonary hypertension, and will also introduce the potential therapeutic value of modulating this pathway. |
| | |
Authors:
|
B R Lindman; M M Chakinala |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: International journal of clinical practice. Supplement Volume: - ISSN: 1368-504X ISO Abbreviation: Int J Clin Pract Suppl Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-13 Completed Date: 2011-02-03 Revised Date: 2011-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9712380 Medline TA: Int J Clin Pract Suppl Country: England |
Other Details:
|
Languages: eng Pagination: 15-22 Citation Subset: IM |
Copyright Information:
|
© 2010 Blackwell Publishing Ltd. |
Affiliation:
|
Department of Internal Medicine, Washington University School of Medicine, St Louis, MO, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antihypertensive Agents
/
therapeutic use Aortic Valve Stenosis / physiopathology Cardiomyopathies / physiopathology Cyclic GMP / metabolism* Cyclic Nucleotide Phosphodiesterases, Type 5 / metabolism Diastole / physiology Heart Failure / physiopathology, therapy Humans Hypertension, Pulmonary / drug therapy, physiopathology* Hypertrophy, Left Ventricular / physiopathology* Nitric Oxide / metabolism* Oxidative Stress / physiology Phosphodiesterase 5 Inhibitors / pharmacology Signal Transduction / physiology Stroke Volume / physiology Systole / physiology Ventricular Dysfunction, Left / physiopathology Ventricular Remodeling / physiology |
| Grant Support | |
ID/Acronym/Agency:
|
KL2 RR024994-01/RR/NCRR NIH HHS; UL1 RR024992-01/RR/NCRR NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Phosphodiesterase 5 Inhibitors; 10102-43-9/Nitric Oxide; 7665-99-8/Cyclic GMP; EC 3.1.4.35/Cyclic Nucleotide Phosphodiesterases, Type 5 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Metabolic and hormonal derangements in pulmonary hypertension: from mouse to man.
Next Document: How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?